Progress of new drugs on relapsed/refractory peripheral T-cell lymphoma / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 321-326, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-863492
ABSTRACT
Peripheral T-cell lymphomas (PTCLs) are a group of heterogeneous diseases originating from post-thymic T-cells, with poor prognosis using traditional therapy, especially in patients with relapsed/refractory PTCLs (r/rPTCLs). In recent years, a variety of new anti-tumor drugs have emerged in the treatment of r/rPTCLs, including different types of enzyme inhibitors, monoclonal antibodies, immunomodulators and immune checkpoint inhibitors, which have been proved to be effective. The discovery and clinical application of new drugs are expected to improve the outcomes of the diseases.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of International Oncology
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS